Assistance Publique Hopitaux De Paris

Research site

France 9 Avenue Charles De Gaulle, 92100 Boulogne-Billancourt, France

21 trials recruiting
Hypertension · Malignant melanoma · Axial spondyloarthritis
Adults and children

About Specializations

Assistance Publique Hopitaux De Paris in Boulogne-Billancourt, France specialises in clinical trials of conditions such as Hypertension, Malignant melanoma, Axial spondyloarthritis, Chronic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The Service de Cardiologie at Assistance Publique Hopitaux De Paris conducts studies aimed at improving outcomes for patients with cardiovascular disease and related risk factors.

Dose optimization of combined cardiovascular agents
Evaluation of heart‑failure endpoints in diabetic populations
Blood‑pressure control strategies in hypertensive cohorts
Safety profiling of novel metabolic‑cardiac therapies

Recent trials explore the impact of vicadrostat together with empagliflozin on reducing cardiovascular death, hospitalization for heart failure, and urgent visits in individuals with type 2 diabetes, hypertension and established disease.

Oncology Trials

Researchers in the cardiology department also lead investigations into neoplasms, focusing on melanoma subtypes that pose significant therapeutic challenges.

Combination immunotherapy with checkpoint inhibitors
Targeted therapy for NRAS‑mutated melanoma
Assessment of progression‑free and overall survival
Adaptive dose‑finding studies for novel agents

Key studies evaluate the efficacy of EIK1001 plus pembrolizumab and the pairing of naporafenib with trametinib in patients with advanced melanoma or unresectable or metastatic NRAS mutant cutaneous melanoma.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

9 Avenue Charles De Gaulle92100 Boulogne-BillancourtFrance

Open in maps ↗

Recruiting now: 21 trials
Conditions studied: 49

More sites in Boulogne-Billancourt France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

56 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Arthritis infective

Recruiting

A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

Registered drug

A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Cutaneous lupus erythematosus

Recruiting

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Non-small cell lung cancer stage III

Recruiting

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Device related infection

Recruiting

Study Comparing Rifabutin and Rifampicin for Adults with Staphylococcal Prosthetic Joint Infection Using DAIR Strategy

Registered drugNo placebo

Study Comparing Rifabutin and Rifampicin for Adults with Staphylococcal Prosthetic Joint Infection Using DAIR Strategy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Rifabutin
Sponsor:Centre Hospitalier De Tourcoing

Contact Research Centre

Human papilloma virus immunisation

Recruiting

Study on the Effectiveness of the Nonavalent HPV Vaccine in Treating Hard-to-Treat Palmar or Plantar Warts in Patients Who Have Not Responded to Two Previous Treatments

Registered drugNo placebo

Study on the Effectiveness of the Nonavalent HPV Vaccine in Treating Hard-to-Treat Palmar or Plantar Warts in Patients Who Have Not Responded to Two Previous Treatments

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Retroperitoneal fibrosis

Recruiting

Study on Stopping Prednisolone Early in Patients with Negative FDG-PET/CT and Idiopathic Retroperitoneal Fibrosis

Registered drugNo placebo

Study on Stopping Prednisolone Early in Patients with Negative FDG-PET/CT and Idiopathic Retroperitoneal Fibrosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Prednisolone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Pneumonia+1

Recruiting

Study on Amoxicillin and Clavulanic Acid for Treating Ventilator-Associated Pneumonia in Intensive Care Patients

Registered drugNo placebo

Study on Amoxicillin and Clavulanic Acid for Treating Ventilator-Associated Pneumonia in Intensive Care Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Staphylococcal infection

Recruiting

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amikacin Sulfate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Myocarditis

Recruiting

Study on Colchicine for Reducing Heart Damage in Patients with Acute Myocarditis

Registered drug

Study on Colchicine for Reducing Heart Damage in Patients with Acute Myocarditis

Registered drug

France

Participants:18–64 years
Substances:Colchicine
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites